[HTML][HTML] Challenges and opportunities for non-antibody scaffold drugs
R Vazquez-Lombardi, TG Phan, C Zimmermann… - Drug discovery today, 2015 - Elsevier
Drug discovery today, 2015•Elsevier
Highlights•Non-antibody scaffold drugs are a promising new class of biologics drugs.•The
first candidate scaffolds are now moving into clinical development and practice.•Challenges
remain and scaffolds will need to be further tailored toward applications where they provide
real advantages over established therapeutics to succeed in a rapidly evolving drug
development landscape.The first candidates from the promising class of small non-antibody
protein scaffolds are now moving into clinical development and practice. Challenges remain …
first candidate scaffolds are now moving into clinical development and practice.•Challenges
remain and scaffolds will need to be further tailored toward applications where they provide
real advantages over established therapeutics to succeed in a rapidly evolving drug
development landscape.The first candidates from the promising class of small non-antibody
protein scaffolds are now moving into clinical development and practice. Challenges remain …
Highlights
- Non-antibody scaffold drugs are a promising new class of biologics drugs.
- The first candidate scaffolds are now moving into clinical development and practice.
- Challenges remain and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果